C3a-induced contraction of guinea pig lung parenchyma: role of cyclooxygenase metabolites

N P StimlerT E Hugli


The complement anaphylatoxin C3a from human or porcine serum contracts isolated peripheral airways from guinea pig in a manner which is independent of histamine release. In order to evaluate the role of arachidonic acid metabolites in the C3a response, dose-response curves for C3a-induced contractions of guinea pig lung strips were compared in the presence and absence of several inhibitors which block metabolism of arachidonic acid at relatively specific steps in the pathways. The inhibitor of leukotriene activity, FPL 55712, and the lipoxygenase inhibitor, nordihydroguiaretic acid (NDGA), had no significant effect on the tissue response to C3a alone or in combination with antihistamine. The cyclooxygenase inhibitors, indomethacin and aspirin, however, both resulted in significant inhibition, causing a shift in the C3a dose-response curve to higher concentrations. When the antihistamine, pyrilamine, was included with either indomethacin or aspirin, the C3a response was inhibited further, although pyrilamine alone had no effect. Thus, C3a-induced contractions of isolated lung parenchyma are mediated primarily by cyclooxygenase metabolites of arachidonic acid. This result is in contrast to the finding that C5a anaphylatoxin media...Continue Reading


Aug 1, 1975·Proceedings of the National Academy of Sciences of the United States of America·M HambergB Samuelsson
Dec 1, 1971·Experimental Cell Research·J P MacManus, J F Whitfield
Feb 1, 1968·The Journal of Experimental Medicine·C G Cochrane, H J Müller-Eberhard
Nov 1, 1980·The Journal of Pharmacy and Pharmacology·N P StimlerT E Hugli
Dec 4, 1981·Molecular and Cellular Biochemistry·T E HugliS Russell

❮ Previous
Next ❯


Jan 1, 1984·Springer Seminars in Immunopathology·T E Hugli
Aug 11, 2005·Current Allergy and Asthma Reports·Marsha Wills-Karp, Joerg Koehl
Jan 1, 1988·Molecular Aspects of Medicine·N C OlsonC E McCall
Jun 1, 1983·Molecular Immunology·T E HugliB W Erickson
Dec 1, 1984·Immunopharmacology·R HueyT E Hugli
Jan 1, 1985·Immunology Letters·Z Fishelson
Feb 26, 1998·Immunopharmacology·J F Regal
Feb 9, 2000·Immunopharmacology·J F Regal, A Klos
Feb 1, 1985·Proceedings of the National Academy of Sciences of the United States of America·U H del BalzoM J Polley
Nov 19, 2005·American Journal of Respiratory and Critical Care Medicine·Seung-Ha LeeChoon-Sik Park
Aug 3, 2004·The Journal of Clinical Investigation·Seiji KawamotoRaif S Geha
Feb 23, 2005·Respiratory Research·Hydar Ali, Reynold A Panettieri
May 1, 1987·Kidney International·A K CheungA L Wayman
May 1, 2007·Bioorganic & Medicinal Chemistry Letters·Frédéric DenonneDong Zou
Apr 1, 1993·Prostaglandins, Leukotrienes, and Essential Fatty Acids·E GulbinsG C Vitale
Aug 21, 2015·Journal of Translational Medicine·Mohammad Afzal KhanDieter Clemens Broering
May 4, 2007·Current Opinion in Pharmacology·Jörg Köhl, Marsha Wills-Karp
Apr 16, 1991·Biochemistry·J A EmberT E Hugli
Dec 1, 1993·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·G P PüschelP Dieter
Jan 1, 1984·International Journal of Developmental Neuroscience : the Official Journal of the International Society for Developmental Neuroscience·G Grassi-ZucconiA Giuditta
Jan 1, 1992·Acta Oto-laryngologica·T HaradaT Matsunaga
Feb 13, 2001·American Journal of Physiology. Lung Cellular and Molecular Physiology·N W LukacsP A Ward
Nov 9, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·J KildsgaardR A Wetsel
Jan 1, 1988·Pulmonary Pharmacology·R R SchellenbergM M Glovsky

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alternative Complement Pathway

The Alternative Complement Pathway is part of the innate immune system, and activation generates membrane attack complexes that kill pathogenic cells. Discover the latest research on the Alternative Complement Pathway.